AnaptysBio completes therapeutic antibody generation project
The pharma partner has received worldwide rights to the development and commercialization of three antibodies generated by AnaptysBio using the SHM-XEL platform, under the collaboration. AnaptysBio is eligible
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.